1. Catalog
  2. Quality Improvement in Hepatology
Quality Improvement in Hepatology
Create Account
Availability
On-Demand
Expires on May 04, 2028
Cost
Member: $0.00
Non-Member: $200.00
Patient: $0.00
Associate: $0.00
Student: $0.00
Early Career: $0.00
Industry Rep: $200.00
Credit Offered
1 AMA PRA Category 1 Credit
1 Participation Credit
  • Description
  • Learning Objectives
  • Faculty and Disclosures
  • Privacy Policy
This interactive, self-paced curriculum equips hepatology and transplant clinicians with practical skills to design, implement, and sustain quality improvement (QI) initiatives in real-world care settings. Across four focused modules, learners will progress from identifying meaningful care gaps to building SMART aims, diagnosing root causes, designing targeted interventions, and testing changes using PDSA cycles and run charts. The program emphasizes hands-on application through case-based scenarios and structured tools—including process maps, driver diagrams, and risk frameworks—to address common challenges such as care coordination gaps, limited access, and workflow inefficiencies. By the end of the course, participants will be prepared to lead data-driven QI projects that improve patient outcomes and embed sustainable change in hepatology practice.
Upon completion of this activity, participants should be able to:
  • Identify and define a hepatology-specific care gap appropriate for quality improvement using process, outcome, and balancing measures.
  • Apply structured QI tools (e.g., process mapping, cause-and-effect analysis, and driver diagrams) to diagnose root causes and design targeted interventions
  • Implement and evaluate iterative tests of change using PDSA cycles and interpret run charts to assess performance over time
  • Develop strategies to troubleshoot barriers and sustain improvement by incorporating risk management, stakeholder engagement, and standardization into clinical workflows

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Planners:
Arpan Patel, MD
Nothing to Disclose

Saroja Bangaru, MD
Nothing to Disclose

Chip Bowman MD MPH
Nothing to Disclose

Janet Gripshover, DNP, MBA, FNP-BC, AF-AASLD
Speaker’s Bureau: AbbVie, Intercept, Gilead

Reviewers and Staff:
Andrew Keaveny, MD, FRCPI, FAASLD
Scientific Consultant: Mallinckrodt, BioVie
Research Grants: HepQuant, BioVie, Mallinckrodt, Gabriel House of Care, River 2 Renal Company
Intellectual Property Rights: UpToDate, Inc.
Leadership in Board/Committee: American Board of Internal Medicine

Bruce Dimmig
Expert Testimony: Intercept, Pfizer, Bayer, Salix, Merck, Madrigal, WebMD, Satellite Bio, Blue Faery

Laura Shelters, MS Ed
Nothing to Disclose

 

 

 

Powered By